Junya Peng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Junya Peng has a total of 92 co-authors. Here are the top co-authors by number of shared publications:
- Yupei Zhao
General Surgery Department, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
7 shared publications - Wenming Wu
The State Key Laboratory for Complex, Severe, and Rare Diseases, Peking Union Medical College Hospital, Beijing, China
4 shared publications Lulu Liu
Institute of Clinical Medicine, PUMCH, Beijing 100730, China
3 shared publications- Lulu Liu
Institute of Clinical Medicine, Peking Union Medical College Hospital, Beijing 100730, China
2 shared publications Menghua Dai
Department of General Surgery, PUMCH, Beijing 100730, China
2 shared publicationsQiang Xu
Department of General Surgery, PUMCH, Beijing 100730, China
2 shared publications
Latest Publications
- Open Access
- 30 July 2026
- Published by MDPI AG in Bioengineering
- Vol. 13 (8) , 879
Isolation and Characterization of Extracellular Vesicles from Human and Mouse Pancreatic Tissue
Extracellular Vesicles (EVs) have been increasingly recognized as mediators of intercellular communication in pancreatic tissues, carrying molecular cargo reflective of their cellular origin; however, their direct isolation from solid tissue remains technically challenging due to the high enzymatic activity, lipid content, and structural fragility of the pancreas. Here, we establish a pancreas-adapted and reproducible workflow for the isolation of EVs directly from human and mouse pancreatic tissues across tumor and non-tumorous contexts. This approach integrates controlled tissue processing, gentle enzymatic-mechanical dissociation, and sequential centrifugation to enable efficient vesicle recovery while preserving structural integrity and minimizing contamination. The isolated EVs exhibited characteristic size distributions, intact morphology, and enrichment of canonical EV markers, accompanied by depletion of intracellular components. Quantitative analyses demonstrated high reproducibility across independent isolations, with a coefficient of variation of less than 6%. Proteomic profiling revealed selective enrichment of vesicle-associated proteins and preservation of molecular differences between tumor and normal pancreatic tissues, indicating that tissue-derived EVs retain disease-associated protein signatures. Together, these results establish a standardized framework for pancreas-derived EV isolation that supports reproducible downstream analyses and facilitates molecular characterization of pancreatic tissues.
- 30 July 2026
- Published by MDPI AG in Bioengineering
- Vol. 13 (8) , 879
Open AccessIsolation and Characterization of Extracellular Vesicles from Human and Mouse Pancreatic Tissue
Extracellular Vesicles (EVs) have been increasingly recognized as mediators of intercellular communication in pancreatic tissues, carrying molecular cargo reflective of their cellular origin; however, their direct isolation from solid tissue remains technically challenging due to the high enzymatic activity, lipid content, and structural fragility of the pancreas. Here, we establish a pancreas-adapted and reproducible workflow for the isolation of EVs directly from human and mouse pancreatic tissues across tumor and non-tumorous contexts. This approach integrates controlled tissue processing, gentle enzymatic-mechanical dissociation, and sequential centrifugation to enable efficient vesicle recovery while preserving structural integrity and minimizing contamination. The isolated EVs exhibited characteristic size distributions, intact morphology, and enrichment of canonical EV markers, accompanied by depletion of intracellular components. Quantitative analyses demonstrated high reproducibility across independent isolations, with a coefficient of variation of less than 6%. Proteomic profiling revealed selective enrichment of vesicle-associated proteins and preservation of molecular differences between tumor and normal pancreatic tissues, indicating that tissue-derived EVs retain disease-associated protein signatures. Together, these results establish a standardized framework for pancreas-derived EV isolation that supports reproducible downstream analyses and facilitates molecular characterization of pancreatic tissues.
- Open Access
- 11 June 2026
- Published by MDPI AG in Bioengineering
- Vol. 13 (6) , 678
A Micro-Quantitative and FFPE-Compatible Workflow for Immunohistochemistry-Guided Spatial Proteomic Analysis of Cellular Subpopulations Within the Tumor Microenvironment
Understanding the spatial proteomic landscape of human tumors is essential for dissecting cellular heterogeneity and microenvironmental interactions in cancer biology. Traditional bulk proteomic approaches, however, obscure spatial information and average out signals from distinct cell populations. Here, we present a detailed and reproducible micro-quantitative protocol for spatially resolved proteomic analysis of specific cellular subpopulations isolated from immunohistochemistry (IHC)-labeled formalin-fixed paraffin-embedded (FFPE) tissue sections using laser microdissection (LMD). By combining IHC staining to visually define phenotypically distinct cells within preserved tissue architecture and precise LMD capture, approximately 6000 target cells can be isolated per sample for downstream proteomic quantification. Despite the ultra-low input, optimized lysis and digestion steps ensure consistent peptide recovery and highly reproducible label-free LC–MS/MS data across replicates. Integrating immunohistochemistry staining-guided spatial sampling with ultrasensitive quantitative proteomics, this workflow enables reliable cell-type-specific profiling directly within human tumor tissues. The protocol bridges histopathology and proteomics, offering a practical framework for translational research exploring spatial protein signatures and tumor microenvironmental heterogeneity.
- 11 June 2026
- Published by MDPI AG in Bioengineering
- Vol. 13 (6) , 678
Open AccessA Micro-Quantitative and FFPE-Compatible Workflow for Immunohistochemistry-Guided Spatial Proteomic Analysis of Cellular Subpopulations Within the Tumor Microenvironment
Understanding the spatial proteomic landscape of human tumors is essential for dissecting cellular heterogeneity and microenvironmental interactions in cancer biology. Traditional bulk proteomic approaches, however, obscure spatial information and average out signals from distinct cell populations. Here, we present a detailed and reproducible micro-quantitative protocol for spatially resolved proteomic analysis of specific cellular subpopulations isolated from immunohistochemistry (IHC)-labeled formalin-fixed paraffin-embedded (FFPE) tissue sections using laser microdissection (LMD). By combining IHC staining to visually define phenotypically distinct cells within preserved tissue architecture and precise LMD capture, approximately 6000 target cells can be isolated per sample for downstream proteomic quantification. Despite the ultra-low input, optimized lysis and digestion steps ensure consistent peptide recovery and highly reproducible label-free LC–MS/MS data across replicates. Integrating immunohistochemistry staining-guided spatial sampling with ultrasensitive quantitative proteomics, this workflow enables reliable cell-type-specific profiling directly within human tumor tissues. The protocol bridges histopathology and proteomics, offering a practical framework for translational research exploring spatial protein signatures and tumor microenvironmental heterogeneity.
- 6 June 2026
- Published by Elsevier in Science Bulletin
- Vol. 71 (16) , 4138-4143
AGR2-high cells drive a FOXM1-mediated pro-malignancy program in non-functional pancreatic neuroendocrine tumors (NF-PanNETs) and informatively predict patient outcomes
- 6 June 2026
- Published by Elsevier in Science Bulletin
- Vol. 71 (16) , 4138-4143
AGR2-high cells drive a FOXM1-mediated pro-malignancy program in non-functional pancreatic neuroendocrine tumors (NF-PanNETs) and informatively predict patient outcomes
- 30 April 2026
- Published by Elsevier in Cancer Cell
- Vol. 44 (6) , 1270-1289.e11
A conserved re-epithelialization program underlies malignancy in pancreatic ductal adenocarcinoma
- 30 April 2026
- Published by Elsevier in Cancer Cell
- Vol. 44 (6) , 1270-1289.e11
A conserved re-epithelialization program underlies malignancy in pancreatic ductal adenocarcinoma
- Open Access
- 1 April 2026
- Published by AME Publishing Company in Chinese Clinical Oncology
- Vol. 15 (2) , 32
Genome-wide 5-hydroxymethylcytosine in circulating cell-free DNA reflects DNA methylation dynamics for non-invasive detection of early hepatocellular carcinoma
Background: Early hepatocellular carcinoma (HCC) remains difficult to diagnose because of its insidious and asymptomatic onset. Liquid biopsy provides a promising non-invasive approach for early tumor detection. 5-Hydroxymethylcytosine (5-hmC), the oxidation product of 5-methylcytosine (5-mC), has emerged as an informative epigenetic mark reflecting tumor-associated alterations during hepatocarcinogenesis. Methods: Using an XGBoost-based ensemble learning framework, we identified cfDNA 5-hmC markers that defined an early HCC 5-hmC signature (eHMS). The signature was assessed in training and validation cohorts using receiver operating characteristic (ROC) analysis, with the area under the curve (AUC) as the primary performance metric. Results: We defined a 19-gene cfDNA 5-hmC signature (eHMS), which showed high diagnostic accuracy for early HCC across multiple precancerous states, with AUCs of 92.3% (healthy controls vs. early HCC), 82.5% [benign liver lesions (BLL) vs. early HCC], 78.8% [chronic hepatitis B (CHB) vs. early HCC], 81.3% (liver cirrhosis vs. early HCC), and 89.4% when pooling all non-HCC, further validated in an external cfDNA cohort (AUC =93.5%). When traced to tissue 5-mC, the 5-mC-related eHMS (MeHMS) score distinguished tumors from adjacent tissues with an AUC of 99.9% and showed improved discriminatory performance compared with alpha-fetoprotein (AFP, AUC =71.5%). Moreover, the signature may reflect early metabolic reprogramming and provide prognostic value by stratifying patients for survival and disease progression. Conclusions: Our findings indicate that the eHMS represents a promising biomarker for liquid biopsy in early HCC surveillance.
- 1 April 2026
- Published by AME Publishing Company in Chinese Clinical Oncology
- Vol. 15 (2) , 32
Open AccessGenome-wide 5-hydroxymethylcytosine in circulating cell-free DNA reflects DNA methylation dynamics for non-invasive detection of early hepatocellular carcinoma
Background: Early hepatocellular carcinoma (HCC) remains difficult to diagnose because of its insidious and asymptomatic onset. Liquid biopsy provides a promising non-invasive approach for early tumor detection. 5-Hydroxymethylcytosine (5-hmC), the oxidation product of 5-methylcytosine (5-mC), has emerged as an informative epigenetic mark reflecting tumor-associated alterations during hepatocarcinogenesis. Methods: Using an XGBoost-based ensemble learning framework, we identified cfDNA 5-hmC markers that defined an early HCC 5-hmC signature (eHMS). The signature was assessed in training and validation cohorts using receiver operating characteristic (ROC) analysis, with the area under the curve (AUC) as the primary performance metric. Results: We defined a 19-gene cfDNA 5-hmC signature (eHMS), which showed high diagnostic accuracy for early HCC across multiple precancerous states, with AUCs of 92.3% (healthy controls vs. early HCC), 82.5% [benign liver lesions (BLL) vs. early HCC], 78.8% [chronic hepatitis B (CHB) vs. early HCC], 81.3% (liver cirrhosis vs. early HCC), and 89.4% when pooling all non-HCC, further validated in an external cfDNA cohort (AUC =93.5%). When traced to tissue 5-mC, the 5-mC-related eHMS (MeHMS) score distinguished tumors from adjacent tissues with an AUC of 99.9% and showed improved discriminatory performance compared with alpha-fetoprotein (AFP, AUC =71.5%). Moreover, the signature may reflect early metabolic reprogramming and provide prognostic value by stratifying patients for survival and disease progression. Conclusions: Our findings indicate that the eHMS represents a promising biomarker for liquid biopsy in early HCC surveillance.
- Open Access
- 9 November 2025
- Published by MDPI AG in Bioengineering
- Vol. 12 (11) , 1222
A Protocol for the In Vitro Culturing of Vascularized Pancreatic Islet Organoids
This study presents a protocol for co-culturing pancreatic islet cell clusters derived from pancreatic tissue with human umbilical vein endothelial cells (HUVECs) on Matrigel using a specialized culture medium to form vascularized pancreatic islet organoids. We established a novel culture system for vascularized pancreatic islet organoids and compared the survival and insulin secretion capabilities of pancreatic islet cells in the presence and absence of glucose stimulation. Our results indicate that matrix adhesive materials can effectively facilitate the self-assembly of the vascularized endothelial cell–pancreatic islet organoids complex. Vascularized HUVEC prolongs the survival of pancreatic islet organoids in vitro. Moreover, the interaction between vascularized HUVEC and pancreatic islets significantly enhances the insulin secretion ability in response to glucose stimulation. This study reports a protocol for the long-term in vitro culture of pancreatic islet organoids, offering methods for the vascularization of pancreatic islet organoids on Matrigel. These data contribute to the understanding of how vascularization impacts the fate and function of pancreatic islet organoids, although the specific mechanism still requires further clarification.
- 9 November 2025
- Published by MDPI AG in Bioengineering
- Vol. 12 (11) , 1222
Open AccessA Protocol for the In Vitro Culturing of Vascularized Pancreatic Islet Organoids
This study presents a protocol for co-culturing pancreatic islet cell clusters derived from pancreatic tissue with human umbilical vein endothelial cells (HUVECs) on Matrigel using a specialized culture medium to form vascularized pancreatic islet organoids. We established a novel culture system for vascularized pancreatic islet organoids and compared the survival and insulin secretion capabilities of pancreatic islet cells in the presence and absence of glucose stimulation. Our results indicate that matrix adhesive materials can effectively facilitate the self-assembly of the vascularized endothelial cell–pancreatic islet organoids complex. Vascularized HUVEC prolongs the survival of pancreatic islet organoids in vitro. Moreover, the interaction between vascularized HUVEC and pancreatic islets significantly enhances the insulin secretion ability in response to glucose stimulation. This study reports a protocol for the long-term in vitro culture of pancreatic islet organoids, offering methods for the vascularization of pancreatic islet organoids on Matrigel. These data contribute to the understanding of how vascularization impacts the fate and function of pancreatic islet organoids, although the specific mechanism still requires further clarification.
- Open Access
- 1 May 2025
- Published by Wiley in The Journal of Pathology: Clinical Research
- Vol. 11 (3) , e70029
Emerging pathological diagnostic strategies for solid pseudopapillary neoplasm of the pancreas: insights from omics and innovative techniques
Solid pseudopapillary neoplasm (SPN) of the pancreas is a rare, low‐grade malignant tumor, representing 0.9–2.7% of all exocrine pancreatic tumors. SPN patients generally have a favorable prognosis with a 5‐year survival rate exceeding 95% following complete surgical resection. Accurate diagnosis is crucial to avoid unnecessary treatments. Currently, SPN diagnosis relies on imaging techniques such as CT and MRI, along with immunohistochemical analysis of biopsy and resection samples. The main challenge in diagnosis is the potential inability to accurately identify recurrent or metastatic SPN, as well as ‘malignant’ SPN, due to the lack of specific biomarkers. Advances in high‐throughput omics technologies, including genomics, transcriptomics, proteomics and metabolomics, have opened new avenues for identifying novel biomarkers for SPN. Additional, liquid biopsy techniques have enabled more comprehensive analysis of biosamples such as pancreatic cyst fluid, offering promising prospects for preoperative diagnosis. This review highlights recent research on SPN diagnosis, focusing on immunohistochemical markers, tissue sampling methods and the potential of omics approaches. It also discusses the challenges and opportunities in improving diagnostic accuracy, particularly for high‐grade and metastatic SPNs.
- 1 May 2025
- Published by Wiley in The Journal of Pathology: Clinical Research
- Vol. 11 (3) , e70029
Open AccessEmerging pathological diagnostic strategies for solid pseudopapillary neoplasm of the pancreas: insights from omics and innovative techniques
Solid pseudopapillary neoplasm (SPN) of the pancreas is a rare, low‐grade malignant tumor, representing 0.9–2.7% of all exocrine pancreatic tumors. SPN patients generally have a favorable prognosis with a 5‐year survival rate exceeding 95% following complete surgical resection. Accurate diagnosis is crucial to avoid unnecessary treatments. Currently, SPN diagnosis relies on imaging techniques such as CT and MRI, along with immunohistochemical analysis of biopsy and resection samples. The main challenge in diagnosis is the potential inability to accurately identify recurrent or metastatic SPN, as well as ‘malignant’ SPN, due to the lack of specific biomarkers. Advances in high‐throughput omics technologies, including genomics, transcriptomics, proteomics and metabolomics, have opened new avenues for identifying novel biomarkers for SPN. Additional, liquid biopsy techniques have enabled more comprehensive analysis of biosamples such as pancreatic cyst fluid, offering promising prospects for preoperative diagnosis. This review highlights recent research on SPN diagnosis, focusing on immunohistochemical markers, tissue sampling methods and the potential of omics approaches. It also discusses the challenges and opportunities in improving diagnostic accuracy, particularly for high‐grade and metastatic SPNs.
- 8 April 2024
- Published by Elsevier in Science Bulletin
- Vol. 69 (19) , 2987-2992
Uncovering chromatin accessibility and cancer diagnostic potential via cell-free DNA utilization
- 8 April 2024
- Published by Elsevier in Science Bulletin
- Vol. 69 (19) , 2987-2992
Uncovering chromatin accessibility and cancer diagnostic potential via cell-free DNA utilization
- Open Access
- 3 April 2024
- Published by Wolters Kluwer Health in American Journal of Surgical Pathology
- Vol. 48 (5) , 511-520
ABCD1 as a Novel Diagnostic Marker for Solid Pseudopapillary Neoplasm of the Pancreas
The diagnosis of solid pseudopapillary neoplasm of the pancreas (SPN) can be challenging due to potential confusion with other pancreatic neoplasms, particularly pancreatic neuroendocrine tumors (NETs), using current pathological diagnostic markers. We conducted a comprehensive analysis of bulk RNA sequencing data from SPNs, NETs, and normal pancreas, followed by experimental validation. This analysis revealed an increased accumulation of peroxisomes in SPNs. Moreover, we observed significant upregulation of the peroxisome marker ABCD1 in both primary and metastatic SPN samples compared with normal pancreas and NETs. To further investigate the potential utility of ABCD1 as a diagnostic marker for SPN via immunohistochemistry staining, we conducted verification in a large-scale patient cohort with pancreatic tumors, including 127 SPN (111 primary, 16 metastatic samples), 108 NET (98 nonfunctional pancreatic neuroendocrine tumor, NF-NET, and 10 functional pancreatic neuroendocrine tumor, F-NET), 9 acinar cell carcinoma (ACC), 3 pancreatoblastoma (PB), 54 pancreatic ductal adenocarcinoma (PDAC), 20 pancreatic serous cystadenoma (SCA), 19 pancreatic mucinous cystadenoma (MCA), 12 pancreatic ductal intraepithelial neoplasia (PanIN) and 5 intraductal papillary mucinous neoplasm (IPMN) samples. Our results indicate that ABCD1 holds promise as an easily applicable diagnostic marker with exceptional efficacy (AUC=0.999, sensitivity=99.10%, specificity=100%) for differentiating SPN from NET and other pancreatic neoplasms through immunohistochemical staining.
- 3 April 2024
- Published by Wolters Kluwer Health in American Journal of Surgical Pathology
- Vol. 48 (5) , 511-520
Open AccessABCD1 as a Novel Diagnostic Marker for Solid Pseudopapillary Neoplasm of the Pancreas
The diagnosis of solid pseudopapillary neoplasm of the pancreas (SPN) can be challenging due to potential confusion with other pancreatic neoplasms, particularly pancreatic neuroendocrine tumors (NETs), using current pathological diagnostic markers. We conducted a comprehensive analysis of bulk RNA sequencing data from SPNs, NETs, and normal pancreas, followed by experimental validation. This analysis revealed an increased accumulation of peroxisomes in SPNs. Moreover, we observed significant upregulation of the peroxisome marker ABCD1 in both primary and metastatic SPN samples compared with normal pancreas and NETs. To further investigate the potential utility of ABCD1 as a diagnostic marker for SPN via immunohistochemistry staining, we conducted verification in a large-scale patient cohort with pancreatic tumors, including 127 SPN (111 primary, 16 metastatic samples), 108 NET (98 nonfunctional pancreatic neuroendocrine tumor, NF-NET, and 10 functional pancreatic neuroendocrine tumor, F-NET), 9 acinar cell carcinoma (ACC), 3 pancreatoblastoma (PB), 54 pancreatic ductal adenocarcinoma (PDAC), 20 pancreatic serous cystadenoma (SCA), 19 pancreatic mucinous cystadenoma (MCA), 12 pancreatic ductal intraepithelial neoplasia (PanIN) and 5 intraductal papillary mucinous neoplasm (IPMN) samples. Our results indicate that ABCD1 holds promise as an easily applicable diagnostic marker with exceptional efficacy (AUC=0.999, sensitivity=99.10%, specificity=100%) for differentiating SPN from NET and other pancreatic neoplasms through immunohistochemical staining.
- Open Access
- 1 January 2018
- Published by SAGE Publications in Breast Cancer: Basic and Clinical Research
- Vol. 12
Roles of Extracellular Vesicles in Metastatic Breast Cancer
Cells can secrete extracellular vesicles (EVs) to communicate with neighboring or distant cells by EVs which are composed of a lipid bilayer containing transmembrane proteins and enclosing cytosolic proteins, lipids, and nucleic acids. Breast Cancer is the most frequently diagnosed malignancy with more than 1 million new cases each year and ranks the leading cause of cancer mortality in women worldwide. In this review, we will discuss recent progresses of the roles and mechanisms of cancer-derived EVs in metastatic breast cancer, with a special attention on tumor microenvironment construction, progression, and chemo/radiotherapy responses. This review also covers EV roles as biomarker and therapeutic target in clinical application.
- 1 January 2018
- Published by SAGE Publications in Breast Cancer: Basic and Clinical Research
- Vol. 12
Open AccessRoles of Extracellular Vesicles in Metastatic Breast Cancer
Cells can secrete extracellular vesicles (EVs) to communicate with neighboring or distant cells by EVs which are composed of a lipid bilayer containing transmembrane proteins and enclosing cytosolic proteins, lipids, and nucleic acids. Breast Cancer is the most frequently diagnosed malignancy with more than 1 million new cases each year and ranks the leading cause of cancer mortality in women worldwide. In this review, we will discuss recent progresses of the roles and mechanisms of cancer-derived EVs in metastatic breast cancer, with a special attention on tumor microenvironment construction, progression, and chemo/radiotherapy responses. This review also covers EV roles as biomarker and therapeutic target in clinical application.